Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021;589(7841):270-275.

Oweida AJ, Mueller AC, Piper M, Milner D, Van Court B, Bhatia S, et al. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. Cancer Immunol Immunother. 2021;70(4):989-1000.

Rijo MP, Diani-Moore S, Yang C, Zhou P, Rifkind AB. Roles of the ubiquitin ligase CUL4B and ADP-ribosyltransferase TiPARP in TCDD-induced nuclear export and proteasomal degradation of the transcription factor AHR. J Biol Chem. 2021;297(2):100886.

Cacciatore S, Wium M, Licari C, Ajayi-Smith A, Masieri L, Anderson C, et al. Inflammatory metabolic profile of South African patients with prostate cancer. Cancer Metab. 2021;9(1):29.

Weiner AB, Vidotto T, Liu Y, Mendes AA, Salles DC, Faisal FA, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021;12(1):935.

Hissong E, Yantiss RK. The Frontiers of Appendiceal Controversies: Mucinous Neoplasms and Pseudomyxoma Peritonei. Am J Surg Pathol. 2021;Publish Ahead of Print.

Rendeiro AF, Vorkas CK, Krumsiek J, Singh HK, Kapadia SN, Cappelli LV, et al. Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment. Front Immunol. 2021;12:809937.

Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, et al. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. J Pathol. 2021;253(3):292-303.

Shin J-, Choe D, Ransegnola B, Hong H-, Onyekwere I, Cross T, et al. A multifaceted cellular damage repair and prevention pathway promotes high-level tolerance to β-lactam antibiotics. EMBO Rep. 2021;22(2):e51790.

Vaisitti T, Arruga F, Vitale N, Lee T-, Ko M, Chadburn A, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021;137(24):3365-3377.